Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - prazosin hydrochloride, quantity: 1.1 mg (equivalent: prazosin, qty 1 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; polysorbate 80 - in patients with hypertension: prazosin is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a general treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long term oral administration. prazosin can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure: prazosin is indicated in the treatment of severe refractory congestive heart failure. prazosin may be added to the therapeutic regimen in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease: prazosin is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia: prazosin is indicated as an adjunct in the symptomatic treatment of urinary obstruction c

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - prazosin hydrochloride 1.1mg equivalent to 1 mg prazosin - tablet - 1 mg - active: prazosin hydrochloride 1.1mg equivalent to 1 mg prazosin excipient: gelatin lactose monohydrate magnesium stearate maize starch purified talc

Namibia - English - Namibia Medicines Regulatory Council

pharmacare limited - prazosin hcl 1 mg - tablet - prazosin hcl 1 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - tablet - see ingredients - each tablet contains prazosin hydrochloride equivalent to prazosin 1 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

lennon -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - prazosin hydrochloride, quantity: 5.5 mg (equivalent: prazosin, qty 5 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; polysorbate 80 - in patients with hypertension: prazosin is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a general treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long term oral administration. prazosin can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure: prazosin is indicated in the treatment of severe refractory congestive heart failure. prazosin may be added to the therapeutic regimen in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease: prazosin is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia: prozosin is indicated as an adjunct in the symptomatic treatment of urinary obstruction c

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - prazosin hydrochloride, quantity: 2.2 mg (equivalent: prazosin, qty 2 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; polysorbate 80 - in patients with hypertension: prazosin is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a general treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long term oral administration. prazosin can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure. prazosin is indicated in the treatment of severe refractory congestive heart failure. prazosin may be added to the therapeutic regimen in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease: prazosin is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia: prazosin is indicated as an adjunct in the symptomatic treatment of urinary obstruction c

Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - prazosin hydrochloride - tablets - 1 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - prazosin hydrochloride - tablets - 2 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - prazosin hydrochloride - tablets - 5 milligram